Human immunodeficiency virus infection, anemia, and survival

Research output: Contribution to journalArticle

Abstract

Anemia, a common hematologic complication in human immunodeficiency virus (HIV)-infected patients, can be caused by mechanisms including infections, neoplasms, or drug treatment. Studies have consistently found anemia to be associated with reduced survival, even when potentially confounding factors were controlled for. Importantly, recovery from anemia has been shown to reduce this risk to approximately the same level as seen among patients never having had anemia. Although anemia traditionally has been treated with blood transfusions, recent studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in elevating hematocrit values and reducing transfusion requirements in HIV-infected patients who have endogenous erythropoietin levels of ≤500 IU/L. Therapy with r-HuEPO has been shown to be safe and well tolerated. In a recent study, moreover, receipt of erythropoietin was associated with a decreased risk of death, whereas transfusion was associated with an increased risk. If these results are confirmed, the link between r-HuEPO and decreased risk of death in HIV- infected patients with anemia will be further strengthened.

Original languageEnglish (US)
Pages (from-to)44-49
Number of pages6
JournalClinical Infectious Diseases
Volume29
Issue number1
StatePublished - 1999

Fingerprint

Virus Diseases
Anemia
Erythropoietin
HIV
Survival
Hematocrit
Blood Transfusion
Therapeutics
Infection
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Immunology

Cite this

Human immunodeficiency virus infection, anemia, and survival. / Moore, Richard D.

In: Clinical Infectious Diseases, Vol. 29, No. 1, 1999, p. 44-49.

Research output: Contribution to journalArticle

@article{69399c1ea64f4c6897e9686de107bf4c,
title = "Human immunodeficiency virus infection, anemia, and survival",
abstract = "Anemia, a common hematologic complication in human immunodeficiency virus (HIV)-infected patients, can be caused by mechanisms including infections, neoplasms, or drug treatment. Studies have consistently found anemia to be associated with reduced survival, even when potentially confounding factors were controlled for. Importantly, recovery from anemia has been shown to reduce this risk to approximately the same level as seen among patients never having had anemia. Although anemia traditionally has been treated with blood transfusions, recent studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in elevating hematocrit values and reducing transfusion requirements in HIV-infected patients who have endogenous erythropoietin levels of ≤500 IU/L. Therapy with r-HuEPO has been shown to be safe and well tolerated. In a recent study, moreover, receipt of erythropoietin was associated with a decreased risk of death, whereas transfusion was associated with an increased risk. If these results are confirmed, the link between r-HuEPO and decreased risk of death in HIV- infected patients with anemia will be further strengthened.",
author = "Moore, {Richard D}",
year = "1999",
language = "English (US)",
volume = "29",
pages = "44--49",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Human immunodeficiency virus infection, anemia, and survival

AU - Moore, Richard D

PY - 1999

Y1 - 1999

N2 - Anemia, a common hematologic complication in human immunodeficiency virus (HIV)-infected patients, can be caused by mechanisms including infections, neoplasms, or drug treatment. Studies have consistently found anemia to be associated with reduced survival, even when potentially confounding factors were controlled for. Importantly, recovery from anemia has been shown to reduce this risk to approximately the same level as seen among patients never having had anemia. Although anemia traditionally has been treated with blood transfusions, recent studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in elevating hematocrit values and reducing transfusion requirements in HIV-infected patients who have endogenous erythropoietin levels of ≤500 IU/L. Therapy with r-HuEPO has been shown to be safe and well tolerated. In a recent study, moreover, receipt of erythropoietin was associated with a decreased risk of death, whereas transfusion was associated with an increased risk. If these results are confirmed, the link between r-HuEPO and decreased risk of death in HIV- infected patients with anemia will be further strengthened.

AB - Anemia, a common hematologic complication in human immunodeficiency virus (HIV)-infected patients, can be caused by mechanisms including infections, neoplasms, or drug treatment. Studies have consistently found anemia to be associated with reduced survival, even when potentially confounding factors were controlled for. Importantly, recovery from anemia has been shown to reduce this risk to approximately the same level as seen among patients never having had anemia. Although anemia traditionally has been treated with blood transfusions, recent studies have shown recombinant human erythropoietin (r-HuEPO) to be effective in elevating hematocrit values and reducing transfusion requirements in HIV-infected patients who have endogenous erythropoietin levels of ≤500 IU/L. Therapy with r-HuEPO has been shown to be safe and well tolerated. In a recent study, moreover, receipt of erythropoietin was associated with a decreased risk of death, whereas transfusion was associated with an increased risk. If these results are confirmed, the link between r-HuEPO and decreased risk of death in HIV- infected patients with anemia will be further strengthened.

UR - http://www.scopus.com/inward/record.url?scp=0032784036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032784036&partnerID=8YFLogxK

M3 - Article

C2 - 10433563

AN - SCOPUS:0032784036

VL - 29

SP - 44

EP - 49

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 1

ER -